Shire publishes Vyvanse study results

Shire has announced the publication of a new study of once-daily Vyvanse (lisdexamfetamine dimesylate) showing the compound significantly improved attention deficit hyperactivity disorder (ADHD) symptoms in adults within the first week of treatment.

The phase III trial data was published in the September issue of the Journal of Clinical Psychiatry.

Shire said these results came from the pivotal trial previously submitted to the US Food and Drug Administration and supported its approval in this indication in April 2008.

The compound was introduced in July 2007 for use in children aged six to 12.

Lenard A Adler, associate professor of psychiatry, neurology and child and adolescent psychiatry at the New York University School of Medicine, said: “This study adds to the growing body of research of ADHD in adults and showed that Vyvanse provided effective symptom control for adults with this disorder.”

He added it is key to realise the key symptoms of ADHD in adults can result in characteristics which can impact on their daily lives, such as a lack of focus and organisation or poor time management.

Earlier this week, Shire announced the results of a multidisciplinary analysis assessing the drug release profiles of Asacol (mesalazine) and Lialda (mesalamine).